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Abstract  
Fibrinogen has a central role in coagulation. Following trauma and perioperatively 
low fibrinogen levels have been found to be risk factors for exaggerated bleeding, 
transfusion needs and adverse outcome. Conversely, treatment with exogenous 
fibrinogen in critically bleeding patients with low fibrinogen levels has been shown 
to decrease transfusion needs. Since following trauma and in many perioperative 
situations fibrinogen is the first coagulation “element” to become critically low, it 
appears reasonable to target fibrinogen in clinical coagulation algorithms aiming 
at early specific and goal-directed treatment. A low fibrinogen can be a low plas-
ma concentration or a low functional fibrinogen as assessed by point-of-care 
techniques like thromboelastography or thromboelastometry. This review sum-
marizes the evidence base for perioperative algorithm based fibrinogen admin-
istration including the exact thresholds for fibrinogen administration used in the 
different algorithms. Algorithm based individualized goal-directed use of fibrino-
gen resulted in highly significant reduction of transfusion needs, adverse out-
comes, in certain studies even mortality and where investigated reduced costs, 
with high safety levels at the same time. Best evidence exists in cardiac surgery, 
followed by trauma, postpartum hemorrhage and liver transplantation. The intro-
duction of these concepts is highly demanding and requires a tremendous educa-
tional effort to familiarize all health care workers with the necessary knowledge 
and the skills of how to run thromboelastometry / thromboelastography tests. Fu-
ture research is needed to compare the efficacy, safety and costs of different al-
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gorithms. This, however, should not prevent us from introducing these expedient 
point-of-care based algorithms clinically today. 
 
Keywords: Fibrinogen, Blood Coagulation, Algorithms, Patient Blood Manage-
ment 
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Introduction 
Fibrinogen has a central role in coagulation. It links platelets and is the substrate 
of the plasmatic coagulation resulting in a mesh network which is essential for 
clot strength 1-3. Following trauma 4-8 and perioperatively 9-13 low fibrinogen levels 
have been found to be risk factors for exaggerated bleeding, transfusion needs 
and adverse outcome. Conversely, treatment with exogenous fibrinogen in criti-
cally bleeding patients with low fibrinogen levels has been shown to decrease 
transfusion needs highly significantly 10,14-17. Fibrinogen molecules are consumed 
for the developing clot whereas most other coagulation factors are reusable en-
zymes. Therefore fibrinogen is the first coagulation factor to become critically low 
during activation of coagulation and bleeding 18-20.  
Consequently targeting fibrinogen as a central element in critical bleeding for ear-
ly specific and goal-directed treatment appears reasonable. The optimal way of 
quickly detect critically low fibrinogen levels, however, is still a matter of debate. 
At certain centers laboratory based fibrinogen concentration measurements are 
the only way of detecting low fibrinogen levels. However, turnaround times of 60-
90 min 21,22 are too high in a critically bleeding patient, fibrinogen concentration 
measurements vary by up to 80% between laboratories 23 and may be influenced 
by the presence of artificial colloids 24,25. Hence thromboelastographic / thrombo-
elastometric techniques are increasingly used to monitor coagulation quickly fol-
lowing trauma and during critical bleeding perioperatively 4,5,10,12,15-17,26. These 
monitoring techniques allow a comprehensive evaluation of the coagulation with-
in 10-20 min with a specific focus on fibrinogen activity including the compromis-
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ing effect of artificial colloids on coagulation 25,27-30. In the following a “low fibrino-
gen level” thus may be based on a low fibrinogen concentration measured in the 
central laboratory or a low fibrinogen activity based on thromboelastographic / 
thromboelastometric evaluation. 
While some may argue that the evidence is still limited justifying the use of fibrin-
ogen for the early goal-directed treatment of coagulopathy or critical bleeding 31, 
we are going to present the emerging concepts in different fields of trauma and 
surgery including their limitation and safety aspects. We are also going to charac-
terize the difference between the prospective randomized study vs. a pragmatic 
algorithm introduction approach in the complex and highly dynamic field of coag-
ulopathy and critical bleeding 32,33. 
 
Trauma 
Trauma is a major health care issue resulting in the annual death of 5-8 million 
people worldwide 20. Bleeding in trauma is due to vascular damage but in approx-
imately 30% of patients also due to coagulopathy of trauma 20,34,35 which devel-
ops already at scene before any medical intervention 36 and which results in a 
several fold increased mortality 34,35,37. Besides hyperfibrinolysis 20,38-40 a low fi-
brinogen level is the hallmark of the coagulopathy of trauma 4-8,20,41. 
Early detection and characterization of coagulopathy following trauma is essential 
for early goal-directed treatment based on algorithms 33. Such algorithms go far 
beyond describing indications for the administration of fibrinogen. They rather 
define the type of coagulation monitoring used and the treatment of all significant 
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alterations of the coagulation system following trauma including targets for the 
interior milieu (pH, temperature, and hemoglobin level), the administration of 
tranexamic acid, prothrombin complex concentrate (PCC), factor XIII and labile 
allogeneic blood products such as red blood cells, plasma and platelets 20,26,42.  
In addition, such point-of-care based algorithms also define when and how to 
monitor the success of the initiated treatment and how to capture the evolution of 
the case over time. This is particularly important in the highly dynamic period fol-
lowing trauma. Fibrinogen is a key element in such algorithms (table 1) but the 
success cannot be ascribed to one single measure. Nevertheless such algo-
rithms are successful in improving coagulation tests 43 reducing the need for al-
logeneic blood transfusions 15,16,44, reducing the incidence of post-traumatic multi-
organ failure, shortening length of hospital stay 16 and they may improve survival 
15,17. The recent study of Nardi et al. 15 deserves special mentioning. They de-
scribe the institutional switch from a rigid 1:1 RBC:plasma transfusion scheme to 
an individualized thromboelastometry and fibrinogen / PCC based early treatment 
algorithm. With this algorithm they could decrease transfusions of allogeneic 
blood products highly significantly with a trend towards improved survival 15. 
At current time, we are unaware of a prospective randomized study assessing 
the effect of the administration of fibrinogen in trauma patients. However, there is 
a prospective randomized study in trauma patients comparing a 1:1:1 
RBC:plasma:platelet transfusion scheme with a laboratory based individualized 
treatment algorithm 45. Although conceptualized as a feasibility trial Nascimento 
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at al. found a near significant two-fold reduction in mortality from 32% to 14% of 
patients treated according to an individualized treatment algorithm 45.  
The use of algorithms or the administration of fibrinogen has to our knowledge 
not resulted in any specific adverse effect in trauma. However, some wonder, 
whether the administration of exogenous fibrinogen would not result in exagger-
ated high postoperative / posttraumatic fibrinogen levels. Post-traumatic fibrino-
gen levels indeed increase significantly in the first week but this increase is not 
any higher in patients treated with exogenous fibrinogen during the initial treat-
ment 46. 
 
Cardiac surgery 
The success of a thromboelastometry, fibrinogen and PCC based coagulation 
algorithm was first shown in a single center study by Görlinger et al. 47. They 
compared the traditional period before (2004) with the period after the introduc-
tion of their algorithm (2009) and found a significant reduction in the use alloge-
neic blood products by 20%, particularly RBC (-19%) and plasma (-94%) with a 
slight but significant increase in platelet transfusion (+29%); at the same time, 
however, the percentage of patients on dual platelet antagonists increased by 
>400%. Even more importantly, massive transfusion (-50%), surgical re-
exploration (-47%) and thrombotic adverse events (-45%) decreased significantly 
47. A similar algorithm was then tested in a prospective randomized 2-center trial 
in patients with diffuse bleeding after cardiopulmonary bypass and heparin rever-
sal against a traditional algorithm (table 1) 48. Again, a highly significant reduction 
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on RBC transfusions (from 5 to 3) and plasma (from 5 to 0) and the use of re-
combinant factor VIIa (from 24% to 2%) was found while the use of fibrinogen 
concentrate was similar in both groups. Interestingly also the total costs of hemo-
therapy (factor concentrates, allogeneic blood products and coagulation test 
costs) were significantly reduced from 3’109 Euro to 1’658 Euro per patient. The 
most important findings, however, were a significantly reduced rate of adverse 
events (from 38% to 8%) and a reduction in 6 month mortality (from 20% to 4%) 
in patients treated by the thromboelastometry, fibrinogen and PCC based coagu-
lation algorithm 48. Also in patients after aortic surgery with clinically relevant co-
agulopathic bleeding after cardiopulmonary bypass and heparin reversal, the ef-
fect of high dose fibrinogen administration based on thromboelastometry resulted 
in a highly significant reduction in total exposure to allogeneic blood products 
from 13 to 2 units per patient and a concomitant increase of the percentage of 
patients totally avoiding any blood products form 0% to 45% 49. In this study no 
trigger level for the administration of fibrinogen was used but a thromboelastome-
try test (FIBTEM) was done 20 min prior to the end of cardiopulmonary bypass. 
Based on this test and aiming for a FIBTEM MCF of 22 mm the individual dose of 
fibrinogen (median 8 g (IQR 6 – 9 g)) was calculated. In general complex cardiac 
surgery the same approach was followed in a recent prospective randomized 
double-blind study in 116 patients 50. Also in this study the percentage of patients 
avoiding all allogeneic blood products was significantly higher (67% vs. 45%) and 
the amounts of RBCs, plasma and platelet transfused as well as postoperative 
bleeding was significantly lower in the treatment arm 50.  
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There are also prospective randomized studies on the prophylactic use of fibrino-
gen in cardiac surgery. Karlsson et al. found in a small study of 20 patients that a 
preoperative 2 gr dose of fibrinogen (vs. placebo) in patients undergoing CABG 
surgery reduced postoperative blood loss and increased the Hb concentration at 
postoperative day one without effect on transfusion rate 51. A similar approach 
was chosen by Sadeghi et al. 52. In 60 patients undergoing CABG surgery they 
administered 1 gr of fibrinogen (vs. placebo) after anesthesia induction and found 
reduced postoperative bleeding. There was a trend towards fewer patients need-
ing postoperative RBC transfusions but the difference was not statistically signifi-
cant 52. Finally, Tanaka et al. studied 20 patients following valve surgery with 
signs of coagulopathic bleeding 53. They compared a 4 g dose of fibrinogen vs. 
the administration of one unit of apheresis platelets. Patients in the fibrinogen 
group received fewer platelet transfusions and had a lower total donor exposure 
than patients in the platelet group 53.  
No safety issues have been detected in any of the above studies. In contrast, in 
two studies a significant reduction of major adverse events was found 47,48 and in 
one study even mortality was significantly reduced 48. A minor issue is the ques-
tion of whether the intraoperative administration of fibrinogen would result in ex-
aggerated fibrinogen levels postoperatively. This has been specifically assessed 
and clearly shown that the postoperative fibrinogen levels similarly in patients 
with and without intraoperative fibrinogen administration 54. 
Until today it is unclear which algorithm element (thrombelastometry, fibrinogen 
or PCC administration) is most important for the success. Interestingly, already 
 10 
the implementation of any type of thromboelastography and thromboelastometry 
coagulation algorithm results in a significant reduction in the use of allogeneic 
blood products in cardiac surgery 55-57. Nevertheless the study by Weber et al., in 
which an algorithm using primarily fibrinogen and PCC rather than plasma and 
platelets resulting in improved outcome, indicates that factor concentrates may 
significantly contribute to the observed benefit in reduced major adverse events 
and improved survival 48. Another important aspect of such advanced coagulation 
algorithms is the repeated monitoring of the coagulation status of the patient. 
This allows early and specific intervention with a sufficient but moderate dose. 
The effect is then quickly verified and additional drugs may be given if necessary. 
In any case an overtreatment with consecutive hypercoagulability is avoided 
which may explain a reduction in thrombotic complications in some of the studies 
47,48. 
A study similar the one of Rahe-Meyer et al. 49 has recently been performed in 
aortic surgery as a prospective randomized multi-center study 
(https://clinicaltrials.gov/ct2/show/NCT01475669, accessed June 21, 2015). 
However, at current time the results have not been formally published. 
 
Liver surgery and transplantation 
Liver transplantation remains an operation with major blood loss and substantial 
need of allogeneic blood product transfusion, because blood coagulation is al-
tered and often compromised in the recipient 58-63. Since blood loss and blood 
product transfusions remain significant independent risk factors for mortality and 
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adverse outcome 64, ways of detecting and characterizing coagulation problems 
using thromboelastography / thromboelastometry have been sought since many 
years (table 1) 61,62,65. Thromboelastography / thromboelastometry, fibrinogen 
and PCC based algorithms were developed and resulted in conflicting results: 
Rollet et al. could not decrease their need for allogeneic blood products 60, while 
Leon-Justel et al. succeeded in reducing their transfusion needs highly signifi-
cantly 66. Kirchner et al. have shown the safety of such a treatment concept. They 
searched prospectively for hepatic artery and portal vein thrombosis, pulmonary 
embolism, stroke and myocardial infarction and did not find a difference between 
the groups 58.  
To our knowledge, there are no prospective randomized studies on the efficacy 
of fibrinogen in liver surgery and transplantation published.  
 
Postpartum hemorrhage 
Postpartum hemorrhage (PPH) is a major cause of maternal morbidity and mor-
tality worldwide 67,68 and the incidence is increasing in the Western countries 69,70. 
PPH has recently be defined as “active bleeding of >1’000 ml within the 24 hours 
following birth that continues despite the use of initial measures including first-line 
uterotonic agents and uterine massage” 71. Pathophysiology of PPH is a combi-
nation of the following main factors: Uterine atony, trauma to the birth canal, pla-
cental problems (retained, abnormal implantation) and coagulopathy character-
ized by hyperfibrinolysis and low fibrinogen 71,72. For non-obstetricians it is im-
portant to understand that all these factors are present and intertwined, and as a 
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consequence, need to be addressed at the same time, ideally in a common algo-
rithm between obstetricians, anesthesiologists and hematologists. Equally im-
portant is implementing a process to detect women with PPH early. 
The first step in the treatment of PPH related coagulopathy is to stop hyperfibri-
nolysis with tranexamic acid. A first pivotal study was performed by Ducloy-
Bouthors et al. in women with >800 ml of PPH 73. Women randomized to receive 
4 gr of tranexamic acid had less blood loss, less progression to severe PPH and 
received fewer RBC transfusions. Based on this and many other studies the 
World Health Organization recommends treating women with PPH with tranex-
amic acid 
(http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf?ua=1, 
accessed June 21, 2015). The optimal dose of tranexamic acid is unknown at the 
current time but 1-2 gr may be adequate 72. The WOMEN trial in 15’000 women 
with PPH is using assessing a dose of 1 gr followed by 1 gr if bleeding continues 
74. This study is still recruiting 
(https://clinicaltrials.gov/ct2/results?term=NCT00872469&Search=Search, ac-
cessed June 21, 2015).  
A low fibrinogen level was first detected as an independent risk factor for the de-
velopment of severe PPH in 2007 75. A fibrinogen concentration < 2 g/l predicted 
severe PPH with a positive predictive value of 100% 75. However, the association 
of a low fibrinogen level with PPH has been challenged recently 76. Nevertheless 
fibrinogen treatment in severe PPH was at least as efficacious as the administra-
tion of cryoprecipitate 77.  
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Also in PPH, thromboelastography / thromboelastometry guided algorithms are 
feasible, efficient and successful. Such an algorithm has been published recently 
(table 1) 10. By the implementation of their algorithm Mallaiah et al. succeeded 
highly significantly in decreasing the total number of allogeneic blood products 
and major adverse outcomes in women with at least 1’500 ml of blood loss after 
delivery 10.  
At current time there is only one prospective randomized study addressing fibrin-
ogen application in patients with PPH 78. Wikkelso et al. randomized 249 patients 
with PPH to receiving a pre-emptive dose of 2 gr fibrinogen or placebo. The fi-
brinogen concentration before treatment was 4.5 g/l in both groups which is nor-
mal for pregnant women 76,79. Since largely women without coagulopathy were 
included, transfusion outcome was identical in both groups 78. A clinically more 
relevant prospective randomized study is underway 80 in which women with se-
vere PPH and signs of (low) fibrinogen related coagulopathy in thromboelastome-
try after treatment with tranexamic acid (1 gr) will be randomized to receive fi-
brinogen (4-8 gr) or placebo 80. Despite the formal lack of high-quality proof of 
efficacy of fibrinogen treatment in severe PPH in women with low fibrinogen lev-
els and / or signs of fibrinogen related coagulopathy, fibrinogen is recommended 
by the PPH-Consensus Group in Europe 81,82. 
 
Risk 
Safety issues and specific benefits in the various surgical settings and following 
trauma have been presented in the respective chapters above. In addition, pre-
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clinical safety animal data was published 83 and also extensive post-marketing 
pharmacovigilance data was analyzed recently 84. Over a period of 27 years and 
over 2’611’294 g of fibrinogen, representing 652’824 patients across a wide 
range of clinical settings 383 adverse drug reactions were reported 84. Anaphy-
laxis and severe allergic reactions were reported in 20 cases. Five fatal outcomes 
were described but only one case of death was associated with the anaphylactic 
reaction. There were 28 cases of thromboembolic complications of which 16 
were described in the setting of acquired and 12 in congenital fibrinogen defi-
ciency. In 13 of these 16 cases of acquired fibrinogen deficiency, patients re-
ceived other pro-thrombotic products in complex clinical situations. Finally, there 
were 21 cases of suspected viral transmission. With the exception of one case 
with insufficient data, a causal relationship was considered unlikely, because pol-
ymerase chain reaction tests were non-reactive (negative) for the concerned 
batches and other ways of transmission were probable. Such pharmacovigilance 
data may be criticized for incomplete reporting. However, also the reporting of 
adverse events due to allogeneic blood transfusion is known to be largely incom-
plete. In a study on pulmonary adverse effects of allogeneic blood products none 
of 24 cases of expert adjudicated transfusion related lung injury or transfusion 
associated circulatory overload was reported to the blood bank 85. Therefore the 
incidence of potential side effects cannot be assessed by such analyses. Safety 
of fibrinogen or thromboelastometry / thromboelastography, fibrinogen and PCC 
based algorithms can only be assessed in direct comparisons as described in 
detail in the different surgery chapters above. 
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Outlook 
Thromboelastometry / thromboelastography, fibrinogen and PCC based algo-
rithms are highly promising concepts enabling quick and specific treatment of 
coagulation problems perioperatively and after trauma. However, some argue 
that these concepts had never been tested prospectively in a randomized, dou-
ble-blind multi-center study and thus would not be valid. It is certainly crucial to 
assess efficacy and safety of these concepts. However, the introduction of these 
concepts is highly demanding and requires a tremendous educational effort to 
familiarize all health care workers with the necessary knowledge including the 
skills of how to run thromboelastometry / thromboelastography tests. When 
achieved, an equally demanding continuous educational effort aiming at main-
taining knowledge and skills and a long learning curve start until this concept 
works at its best. Once all this is achieved, switching back and forth between a 
traditional allogeneic blood product based treatment concept and a thromboelas-
tometry / thromboelastography and coagulation factor based algorithm is utterly 
impossible.  
Therefore comparing periods before and after introduction (and learning curve) of 
algorithms is pragmatically more appropriate. An important topic for future studies 
is the comparison of different intervention thresholds of specific algorithms. One 
example might be, comparing a maximum clot firmness value in the FIBTEM of 7 
mm vs. 12 mm in trauma patients. Such types of studies could be performed as a 
prospective randomized multi-center study. 
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Conclusions 
Fibrinogen has a central role in coagulation and low fibrinogen levels are associ-
ated with exaggerated bleeding and transfusion needs. Thromboelastopgraphy / 
thromboelastometry, fibrinogen and PCC based algorithms are capable of de-
creasing the need for allogeneic transfusions and improving clinical outcome with 
lower mortality and morbidity in certain situations. This has clearly been shown in 
cardiac surgery and has a high evidence level in trauma. Interestingly, in liver 
transplantation the scientific evidence is not so clear, although thromboelas-
topgraphy / thromboelastometry based treatment algorithms have been intro-
duced over 30 years ago in this very context. In postpartum hemorrhage evi-
dence is emerging that the above mentioned concepts are efficacious as well. 
Therefore future research is warranted, which, however, should not prevent us 
from introducing these expedient point-of-care based algorithms clinically now. 
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Table 1: Trigger values for the administration of fibrinogen concentrate in different clinical settings. Please note that the algorithms in the 
various studies were not limited to the administration of fibrinogen. They also contained information on the monitoring of coagulation and the 
indication for other coagulation products including (in most) the use of allogeneic blood products (RBC, plasma and platelets). 
 
Clinical setting Trigger Fibrinogen dose Reference 
Trauma FIBTEM MCF ≤ 7 mm 2-4 g Nardi et al. 15 
Trauma FIBTEM MCF ≤ 10 mm 2-4 g Schöchl et al. 17 
Trauma FIBTEM MCF < 7 mm 2-4 g Theusinger et al. 26 
Trauma Fibrinogen < 1.5-2 g/L 3-4 g Spahn et al. 20 
Trauma Fibrinogen < 1.5-2 g/L 2-4 g Nienaber et al. 44 
Trauma FIBTEM A10 < 7 mm 3 – 8 g Schöchl et al. 46 
    
Cardiac surgery FIBTEM A10 ≤ 10 mm 
(early after CPB) 
or 
FIBTEM A10 < 15 mm 
(late ongoing bleeding) 
25 – 50 (75) mg/kg Görlinger et al. 47 
 
Cardiac surgery FIBTEM A10 ≤ 10 mm 
(early after CPB) 
or 
FIBTEM A10 < 15 mm 
(late ongoing bleeding) 
25 – 50 (75) mg/kg Weber et al. 48 
Cardiac surgery (CABG) Prophylactic preoperatively 2 g Karlsson et al. 51 
Cardiac surgery (CABG) Prophylactic preoperatively 1 g Sadeghi et al. 52 
Cardiac surgery (valve re-
placement) 
Moderate bleeding 4 g fibrinogen Tanaka et al. 53 
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Cardiac surgery (pediatric) FIBTEM A10 ≤ 5 mm 20 ml/kg FFP Nakayama et al. 56 
    
Liver transplantation FIBTEM MCF ≤ 6 mm n/a Kirchner et al. 58 
Liver transplantation FIBTEM MCF ≤ 6 mm 
or 
Fibrinogen < 1 g/L 
50 mg/kg Roullet et al. 60 
    
Obstetric Fibrinogen < 2 g/L n/a Abdul-Kadir et al. 71 
Obstetric Fibrinogen ≤ 2 g/L 4 g Ahmed et al. 77 
Obstetric Severe PPH with blood 
loss of > 1 liter 
2 g  Wikkelso et al. 78 
Obstetric Fibrinogen < 1.5 g/L  2 – 4 g Girard et al. 81 
Obstetric FIBTEM A5 < 7 mm 
or 
Fibrinogen ≤ 1.5 g/L 
3 g initial dose Mallaiah et al. 10 
    
General Fibrinogen  < 1.5-2 g/L 25 – 50 mg/kg Kozek-Langenecker et al. 42 
General pediatric surgery FIBTEM MCF < 7 mm 
or 
Fibrinogen < 1.5-2 g/L 
30 – 50 mg/kg Kozek-Langenecker et al. 42 
General Fibrinogen ≤ 2 g/L 1-2 g Fenger-Eriksen et al. 14 
 
